Results 71 to 80 of about 14,919 (139)

Proteomic profiling identifies candidate biomarkers for small intestinal neuroendocrine tumours G1 and G2

Journal of Neuroendocrinology, Volume 38, Issue 10, October 2026.
Abstract Although small intestinal neuroendocrine tumours (SI‐NET) Grade 1 (G1) and 2 (G2) are often studied together, clinical course and response to treatment may differ. We hypothesized that these tumour groups express different markers in blood that may inform future treatment strategies. Blood from 107 SI‐NET patients (G1 n = 64, G2 n = 43) and 50
Malin Grönberg, Dimitrios Papantoniou, Eva Tiensuu Janson   +2 more
wiley   +1 more source

RET is a sex-biased regulator of intestinal tumorigenesis

Frontiers in Gastroenterology
Ret is implicated in colorectal cancer (CRC) as both a proto-oncogene and a tumor suppressor. We asked whether RET signaling regulates tumorigenesis in an Apc-deficient preclinical model of CRC.
Sean T. Koester, Sean T. Koester, Naisi Li, Neelendu Dey, Neelendu Dey, Neelendu Dey   +5 more
doaj   +1 more source

Surgical Remission of Diabetes in a Patient With Mutation of RET Proto-Oncogene. [PDF]

AACE Clin Case Rep, 2021
Concepción Zavaleta MJ, Armas Flórez CD, Benites Moya CJ, Plasencia Dueñas EA, Ildefonso Najarro SP, Palomino Taype K, Durand Torres R, Massucco Revoredo F.   +7 more
europepmc   +1 more source

RET Proto-Oncogene Mutational Analysis in 45 Iranian Patients Affected with Medullary Thyroid Carcinoma: Report of a New Variant. [PDF]

J Thyroid Res, 2021
Damavandi E, Vand-Rajabpour F, Javadi-Arjmand M, Mohajeri Tehrani MR, Larijani B, Kabuli M, Ghadami M.   +6 more
europepmc   +1 more source

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

Molecular Oncology
Rearranged during transfection (RET) fusions drive subsets of non‐small cell lung cancer (NSCLC) and papillary thyroid carcinoma (PTC). Despite new selective RET tyrosine kinase inhibitors (TKIs), resistance usually occurs and is often driven by RET ...
Juhyeon Son, Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole V. Bremer, Valentina Foglizzo, Paola Roa, Nickole Sigcha‐Coello, Yi Liao, Eric B. Haura, Alexander Drilon, John M. Koomen, Emiliano Cocco, Uwe Rix   +13 more
doaj   +1 more source

Advanced medullary thyroid cancer: pathophysiology and management

Cancer Management and Research, 2013
Carla Vaz Ferreira, Débora Rodrigues Siqueira, Lucieli Ceolin, Ana Luiza MaiaThyroid Section, Endocrine Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, BrazilAbstract: Medullary thyroid carcinoma (MTC) is a rare malignant ...
Ferreira CV, Siqueira DR, Ceolin L, Maia AL   +3 more
doaj  

Roles of the RET Proto-oncogene in Cancer and Development. [PDF]

JMA J, 2020
Takahashi M, Kawai K, Asai N.
europepmc   +1 more source

Total colonic aganglionosis and cleft palate in a newborn with Janus-cysteine 618 mutation of RET proto-oncogene: a case report. [PDF]

Ital J Pediatr, 2020
Schierz IAM, Cimador M, Giuffrè M, Aiello CM, Antona V, Corsello G, Piro E.   +6 more
europepmc   +1 more source

MEN2 phenotype in a family with germline heterozygous rare RET K666N variant

Endocrinology, Diabetes & Metabolism Case Reports
Multiple endocrine neoplasia type 2 (MEN2) is a hereditary cancer syndrome caused by germline-activating pathogenic variants in the RET proto-oncogene.
A La Greca, D Dawes, M Albuja-Cruz, C Raeburn, L Axell, L Ku, C Klein, C Marshall, L Fishbein   +8 more
doaj   +1 more source

A Brief Review on The Molecular Basis of Medullary Thyroid Carcinoma

Cell Journal, 2016
Approximately 5-10% of all thyroid cancers are medullary thyroid carcinomas (MTC). MTC is mainly sporadic in nature, but 20-30% of cases are hereditary. Genetic testing for hereditary MTC is very important for the patient and his family, but the patients
Mohammadi Masoumeh, Mehdi Hedayati
doaj